Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 2:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Lichen Planopilaris Clear all
Recruiting Phase 2Phase 3 Interventional

A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris

NCT07532603
View directory record Official record
Conditions
Lichen Planopilaris
Interventions
Oral Brepocitinib, Placebo
Drug
Lead sponsor
Priovant Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
47
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Early Phase 1 Interventional

Ixekizumab in Adult Patients With Lichen Planus and Lichen Planopilaris

NCT05030415
View directory record Official record
Conditions
Lichen Planus Scalp, Lichen Planus, Lichen Planopilaris
Interventions
Ixekizumab Auto-Injector
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Jul 21, 2026, 2:19 PM EDT
Recruiting Phase 4 Interventional

Nemolizumab to Treat Lichen Planopilaris, a Noncontrolled, Prospective, Pilot Study.

NCT07396168
View directory record Official record
Conditions
Lichen Plano-Pilaris
Interventions
Nemolizumab
Drug
Lead sponsor
The Skin Center Dermatology Group
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New City, New York
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Early Phase 1 Interventional

Role of Neurogenic Inflammation and Topical 6% Gabapentin Therapy in Symptomatic Scarring Alopecia

NCT03346668
View directory record Official record
Conditions
Scarring Alopecia, Frontal Fibrosing Alopecia, Lichen Planopilaris, Central Centrifugal Cicatricial Alopecia, Central Centrifugal Scarring Alopecia
Interventions
Topical gabapentin
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 24, 2024 · Synced Jul 21, 2026, 2:19 PM EDT
Not listed No phase listed Observational

Design and Validation of a New Assessment Tool for Lichen Planopilaris

NCT03082560
View directory record Official record
Conditions
Lichen Planopilaris of Scalp, Lichen Plano-Pilaris, Lichen Planopilaris, Frontal Fibrosing Alopecia
Interventions
Boston Grade of Activity in Lichen Planopilaris
Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 2 Interventional Results available

Ritlecitinib for Cicatricial Alopecia

NCT05549934
View directory record Official record
Conditions
Cicatricial Alopecia
Interventions
PF-06651600
Drug
Lead sponsor
Emma Guttman
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Jul 21, 2026, 2:19 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Expression of Fas Protein in Skin Biopsies of Participants With Scarring Alopecia

NCT00691769
View directory record Official record
Conditions
Central Centrifugal Scarring Alopecia, Lichen Planopilaris, Discoid Lupus Erythematosus
Interventions
Not listed
Lead sponsor
Wake Forest University
Other
Eligibility
30 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Oral Low-Dose Naltrexone for Lichen Planopilaris and Frontal Fibrosing Alopecia

NCT04409041
View directory record Official record
Conditions
Lichen Planopilaris, Frontal Fibrosing Alopecia
Interventions
Low-Dose Naltrexone
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 2 Interventional Results available

PoC Study to Evaluate the Efficacy and Safety of Secukinumab 300 mg in Patients With Lichen Planus

NCT04300296
View directory record Official record
Conditions
Lichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen Planopilaris
Interventions
secukinumab 300 mg Q4W, secukinumab 300 mg Q2W, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
15
States / cities
Birmingham, Alabama • Thousand Oaks, California • Cromwell, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Jul 21, 2026, 2:19 PM EDT
Recruiting Phase 2 Interventional

Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris

NCT07487948
View directory record Official record
Conditions
Central Centrifugal Cicatricial Alopecia, Lichen Planopilaris
Interventions
Delgocitinib
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 2 Interventional Results available

A Study of Deucravacitinib to Treat LPP and FFA

NCT06091956
View directory record Official record
Conditions
Lichen Planopilaris
Interventions
Deucravacitinib
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Scottsdale, Arizona • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 7, 2025 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 2 Interventional Results available

Valchlor in the Treatment of Lichen Planopilaris

NCT03417141
View directory record Official record
Conditions
Lichen Planopilaris
Interventions
Mechlorethamine 0.016% Top Gel
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Jul 21, 2026, 2:19 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Mechanical Intervention on the Scalp Microbiome: Setting the Stage for the Future Management of Cicatricial Alopecias

NCT06357169
View directory record Official record
Conditions
Lichen Planopilaris of Scalp, Alopecia Areata
Interventions
Venus Glow
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 35 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pain Outcomes Following Intralesional Corticosteroid Injections

NCT03630198
View directory record Official record
Conditions
Keloid, Alopecia Areata, Acne, Hypertrophic Scar, Epidermal Inclusion Cyst, Frontal Fibrosing Alopecia, Lichen Plano-Pilaris, Keratoacanthoma, Plaque Psoriasis, Lichen Simplex Chronicus, Prurigo Nodularis, Nummular Eczema, Granuloma Annulare, Morphea, Lichen Planus
Interventions
Corticosteroid with lidocaine, Corticosteroid with normal saline
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
12 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 10, 2021 · Synced Jul 21, 2026, 2:19 PM EDT